Zacks Investment Research downgraded shares of Millendo Therapeutics (NASDAQ:MLND) from a hold rating to a sell rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Millendo Therapeutics Inc. is a biopharmaceutical company. It focuses on developing novel treatments for orphan endocrine diseases. The company’s product candidate consists of AZP-531 and ATR-101 which are in clinical stage. Millendo Therapeutics Inc., formerly known as OvaScience Inc., is based in Ann Arbor, United States. “

MLND has been the topic of a number of other research reports. Jefferies Financial Group began coverage on Millendo Therapeutics in a research note on Wednesday, March 13th. They set a buy rating and a $22.00 price target on the stock. ValuEngine lowered Welbilt from a hold rating to a sell rating in a research note on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of Hold and an average price target of $23.25.

MLND stock opened at $10.67 on Wednesday. Millendo Therapeutics has a 1 year low of $6.77 and a 1 year high of $17.34. The company has a current ratio of 7.83, a quick ratio of 7.83 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $13.36. The stock has a market cap of $142.87 million, a price-to-earnings ratio of -0.61 and a beta of 2.61.

Millendo Therapeutics (NASDAQ:MLND) last posted its earnings results on Wednesday, May 15th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.08). On average, analysts anticipate that Millendo Therapeutics will post -3.25 EPS for the current year.

Several institutional investors have recently modified their holdings of MLND. Great Point Partners LLC purchased a new position in shares of Millendo Therapeutics during the 4th quarter worth $10,240,000. Worth Venture Partners LLC purchased a new position in shares of Millendo Therapeutics during the 4th quarter worth $206,000. BlackRock Inc. purchased a new position in shares of Millendo Therapeutics during the 4th quarter worth $203,000. Tibra Equities Europe Ltd purchased a new position in shares of Millendo Therapeutics during the 1st quarter worth $303,000. Finally, Geode Capital Management LLC purchased a new position in shares of Millendo Therapeutics during the 4th quarter worth $113,000. 44.07% of the stock is currently owned by institutional investors.

About Millendo Therapeutics

Millendo Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of various treatments for orphan endocrine diseases in the United States. The company's lead drug candidates include livoletide, an unacylated ghrelin analogue to treat for Prader-Willi syndrome; and nevanimibe, which is in Phase 2b clinical development for the treatment of congenital adrenal hyperplasia and endogenous Cushing's syndrome.

Featured Article: Understanding each part of a balance sheet

Get a free copy of the Zacks research report on Millendo Therapeutics (MLND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Millendo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millendo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.